Epidarex Capital Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Team Change

Kyp Sirinakis transitioned to Founding Partner, Elizabeth Roper and Peter Finan were promoted to Managing Partner, and Anthony Voveris was promoted to CFO.

Epidarex leadership appointments

Epidarex Capital

epidarex.comJUL 22, 2026

JUL 22, 2026

Investment

RapidPulse closed an oversubscribed $48M Series B, co-led by Medtronic, TechWald Next, and S3 Ventures, with Epidarex participating as an existing investor.

RapidPulse

RapidPulse Epidarex Capital

epidarex.comJUL 17, 2026

JUL 17, 2026

Milestone

NodThera published and presented cardiometabolic clinical data supporting the potential of ruvonoflast to treat inflammation at the source.

NodThera

NodThera Epidarex Capital

epidarex.comJUN 2, 2026

JUN 2, 2026

Talk

NodThera announced a late-breaking oral presentation at the 94th European Atherosclerosis Society Congress.

NodThera

NodThera Epidarex Capital

epidarex.comMAY 19, 2026

MAY 19, 2026

Talk

Nyra Medical presented first-in-human clinical insights across three presentations at EuroPCR.

Nyra Medical

Nyra Medical Epidarex Capital

epidarex.comMAY 15, 2026

MAY 15, 2026

Milestone

Enterprise Therapeutics achieved its primary efficacy outcome in a Phase 2 clinical trial of inhaled ENaC blocker ETD001 for cystic fibrosis.

Enterprise Therapeutics

Enterprise Therapeutics Epidarex Capital

epidarex.comMAY 12, 2026

MAY 12, 2026

Milestone

Theolytics dosed its first patient in the OCTOPOD-IP US Phase 1 trial of THEO-260, an oncolytic immunotherapy for ovarian cancer.

Theolytics

Theolytics Epidarex Capital

epidarex.comMAY 1, 2026

MAY 1, 2026

Exit

Biogen announced its acquisition of portfolio company Apellis Pharmaceuticals, expanding Biogen's immunology and rare disease portfolio.

Apellis Pharmaceuticals

Apellis Pharmaceuticals Epidarex Capital

epidarex.comAPR 2, 2026

APR 2, 2026

Milestone

Lario Therapeutics was awarded $2.4M by The Michael J. Fox Foundation and Wellcome to expand its neuronal calcium channel platform across CNS disorders.

Lario Therapeutics

Lario Therapeutics Epidarex Capital

epidarex.comFEB 19, 2026

FEB 19, 2026

Milestone

Harness Therapeutics nominated HRN001, a first-in-class drug candidate for Huntington's Disease, and established a clinical advisory board.

Harness Therapeutics

Harness Therapeutics Epidarex Capital

epidarex.comFEB 16, 2026

FEB 16, 2026

Team Change

NodThera appointed Geoff McDonough, M.D., as Chief Executive Officer.

NodThera

NodThera Epidarex Capital

epidarex.comFEB 4, 2026

FEB 4, 2026

New Fund

Announced the first close of Epidarex Capital IV, LP, securing more than $145 million to back early-stage UK and US life-science and medtech start-ups.

Epidarex Capital IV first close

Epidarex Capital

epidarex.comJAN 27, 2026

globenewswire.com

JAN 27, 2026

Talk

NodThera presented at the 44th Annual J.P. Morgan Healthcare Conference.

NodThera

NodThera Epidarex Capital

epidarex.comJAN 6, 2026

JAN 6, 2026

Milestone

Leucid Bio and Syenex announced a strategic collaboration for in vivo CAR-T cell engineering.

Leucid Bio

Leucid Bio Epidarex Capital

epidarex.comDEC 15, 2025

DEC 15, 2025

Page 1 of 2

Epidarex Capital | Activity | F4